BioWorld. Link to homepage.
BioWorld
BioWorld MedTech
BioWorld Asia
BioWorld Science
Data Snapshots
BioWorld
BioWorld MedTech
Infographics: Dynamic digital data analysis
Special reports
Aging
Alzheimer's disease
Artificial intelligence
Biosimilars
China CAR T
Coronavirus
Infographics: Dynamic digital data analysis
Israel
IVDs on the rise
Radiopharmaceuticals
Rise of obesity
Top Biopharma Trends of 2023
Top Med-tech Trends of 2023
Top Preclinical Trends of 2023
Premium reports
BioWorld Financings Reports
Disease Incidence & Prevalence Summaries
BioWorld. Link to homepage.
sign in
Sign Out
My Account
Subscribe
BioWorld - Wednesday, May 15, 2024
Home
»
Newsletters
» BioWorld Science
BioWorld Science
Jan. 13, 2011
View Archived Issues
Sangamo BioSciences provides update on product pipeline
Read More
UCB claims new PI3K inhibitors
Read More
Ortho-McNeil-Janssen Pharma patents new gamma-secretase modulators
Read More
Helix BioPharma submits IND to FDA for first-in-human study of L-DOS47
Read More
New cannabinoid CB1 receptor antagonists presented by sanofi-aventis
Read More
Ferrer claims new melatonin MT1 receptor agonists
Read More
Studies investigate effects of intranasal oxytocin in schizophrenia, depression and autism
Read More
AM-095 displays antifibrotic activity in vivo
Read More
JTT-305 shows bone anabolic effects in vivo
Read More
HPRG-induced downregulation of PlGF shows anticancer potential
Read More
BIND Biosciences begins phase I study of BIND-014 in cancer
Read More
Topica begins enrollment in phase I/IIa luliconazole trial in onychomycosis
Read More
Ablynx reports follow-up data from phase I trial of ALX-0141
Read More
AstraZeneca and SCRI join to develop targeted anticancer agent
Read More
Concert Pharma claims new PDE4 inhibitors and TNF-alpha production suppressors
Read More
Allozyne completes phase Ia trial of AZ-01 for multiple sclerosis
Read More
New inhibitors of HCV NS5A developed at Enanta Pharma
Read More
Omthera reports bioavailability data from ECLIPSE trial of Epanova
Read More
Sumavel DosePro obtains marketing approval in Germany and U.K.
Read More
FDA issues positive feedback for design of phase III Davanat trial in colorectal cancer
Read More
Peregrine Pharma begins phase II bavituximab trial in hepatitis C
Read More
Enrollment begins in phase III trial of sapacitabine as front-line AML therapy
Read More
Antigenics becomes Agenus and expands product portfolio
Read More
BioMarin begins phase I/II trial of BMN-673 in genetically defined cancers
Read More
Curis selects CUDC-907 as development candidate for targeted cancer program
Read More